In Print - Ian Spiegel, VMD, MPH, DACVD

J Am Anim Hosp Assoc. 2010 Sep-Oct;46(5):301-11.

Evaluation of the clinical efficacy of pradofloxacin tablets for the treatment of canine pyoderma.

Restrepo C, Ihrke PJ, White SD, Spiegel IB, Affolter VK.

Abstract

A third-generation fluoroquinolone, pradofloxacin (PRA), is currently being developed to treat bacterial infections in dogs. The purpose of this study was to assess the clinical efficacy in 20 dogs affected with superficial and deep pyoderma. An initial aerobic skin culture was performed in dogs with superficial pyoderma; aerobic/anaerobic tissue culture was performed in dogs with deep pyoderma; and skin cytology and biopsies were obtained from all dogs. Pradofloxacin (approximately 3 mg/kg per os [PO]) was administered daily to all dogs. Clinical efficacy was recorded at 4 weeks for dogs with superficial pyoderma and at 3 and 6 weeks for dogs with deep pyoderma. At a mean dosage of 3.7 mg/kg PO once daily, PRA treatment resulted in an excellent to good clinical response within 3 to 6 weeks for all 20 dogs with superficial and deep pyoderma.

Case of the Month - Feline Pemphigus

History
There are ulcerated lesions starting on ear margins, later involving lip margins and periocular area as well as neck. Pruritus started after ulcerated lesions appeared. Skin scraping - neg., DTM - neg., Cytology - PMN's and bacteria, C&S - pending, Dermohistopathology - pending, Bloodwork – normal. She is an outside cat, in a multicat household with no other pets involved. There are no external parasites, owner is not pruritic, no change in diet, on commercial pet food. Gave depo-medrol injection 10 days prior to biopsy. Expect biopsy results in 7 days.

Clinical Consultation
This consultation is based on our phone consultation, submitted history and clinical photos. Thank you for the clinical photos which were helpful. I agree with your suspicion that immune-mediated disease is most likely. Differential diagnoses would include: Erythema multiforme (drug-induced, paraneoplastic, idiopathic) and pemphigus foliaceus (drug-induced, paraneoplastic are possible causes). Lupus erythematosus less commonly occurs in cats so is considered less likely. A cutaneous drug reaction also appears less likely in this case given the cat’s lack of drug history (no medications were being administered prior to the onset of skin disease). Although severe allergic dermatitis can sometimes mimic immune-mediated disease in the cat, the severity of the clinical presentation also makes this less likely. I would also make sure to closely examine mucosal surfaces (perianal, oral)- mucosal surfaces are involved it could indicate vesicular auto-immune disease (pemphigus vulgaris, Stevens-Johnson Syndrome, epidermolysis bullosa acquisita). Immunosuppressive therapy will likely be required to control this disease process. Pending skin biopsies, I would recommend starting this cat on immunosuppressive doses of glucocorticoids (typically 2-3 mg/kg of Prednisolone [over prednisone] divided BID). I start to taper after there has been 75-80% improvement (often within 2 weeks). New lesions should not be developing & older lesions regressing. I would not recommend adding in an additional immunomodulatory agent at this time until after the biopsy results have been reviewed.

Additional follow-up is requested on this case: biopsy report, response to initial therapeutic recommendations, etc. Addendum comments and additional therapeutic recommendations can be made at that time.

Addendum
Per our phone conversation, the dermatopathology report is consistent with feline pemphigus foliaceus. Pemphigus foliaceus (PF) is a cutaneous auto-immune disease which most commonly occurs in middle aged to older cats. Another consideration would be paraneoplastic pemphigus; I would be suspicious of this if the skin lesions are not responding to appropriate therapy (this is typically more difficult to treat). Treatment for PF is often life-long, however some cats will go into extended periods of remission (without maintenance medications). Immunosuppressive therapy is required to control this disease. I recommend immunosuppressive doses of glucocorticoids (typically 2.2 mg/kg of Prednisolone [over prednisone] divided BID). I start to taper after there has been 75-80% improvement (often within 2 weeks). New lesions should not be developing & older lesions regressing. I often recommend a second immunosuppressive agent to control the disease and allow for lower doses of glucocorticoids to be used. Options include Chlorambucil or Atopica (Cyclosporine). Most commonly chlorambucil (0.1-0.2 mg/kg qd-qod) is used; tapered further over time. Monitor for myelosuppression. Obtain a baseline CBC, Chemistry profile & UA prior to initiating therapy. Recheck CBC values every 2 weeks for the first 6-8 weeks; then every 3-6 months. Although PF is often responsive to therapy, it can be a difficult auto-immune disease to manage. If remission is not initially achievable, I recommend referral to a veterinary dermatologist if possible.

Please contact me if this report is inconsistent with your clinical findings or you have additional questions. Please contact me at PetRays phone number listed below.

Terri Bonenberger, DVM
Diplomate, American College Veterinary Dermatology

3 week Update
The ulcerated lesions have healed and scabs have fallen off. The cat is doing very well.

Practical Recent Abstracts

Edited by Jennifer S. Fryer, DVM










The influence of crystalloid type on acid-base and electrolyte status of cats with urethral obstruction

Drobatz KJ, Cole SG. JVECCS 2008; 18: 355 – 361.

To compare the effect of a balanced isotonic crystalloid solution with that of 0.9% sodium chloride on the acid[ndash]base and electrolyte status of cats with urethral obstruction. Randomized prospective clinical trial. Academic veterinary emergency room.

Sixty-eight cats with naturally occurring urethral obstruction. Cats were randomized to receive either a balanced isotonic crystalloid solution (Normosol-R, n=39) or 0.9% sodium chloride (n=29) for fluid therapy. Baseline venous blood gas and blood electrolyte values were obtained at the time of admission and at intervals during the course of therapy. Baseline values were similar between groups.

Cats receiving Normosol-R had a significantly higher blood pH at 12 hours, a significantly greater increase in blood pH from baseline at 6 and 12 hours, as well as a significantly higher blood bicarbonate concentration at 12 hours and a significantly greater increase in blood bicarbonate from baseline at 6 and 12 hours. Conversely, the increase in blood chloride from baseline was significantly higher at 2, 6, and 12 hours in cats receiving 0.9% sodium chloride. There were no significant differences in the rate of decline of blood potassium from baseline between groups. Subgroup analysis of hyperkalemic cats (K+>6.0 mmol/L) and acidemic cats (pH<7.3) style="font-weight: bold;">Efficacy and tolerability of once-daily cephalexin in canine superficial pyoderma: an open controlled study

Toma S, Colombo S, Cornegliani L, Persico P, Galzerano M, Gianino MM, Noli C. Journal of Small Animal Practice 2008; 49: 384 – 39.

Objectives: The aims of this study were to evaluate the efficacy and tolerability of oral cephalexin given at 30 mg/kg once daily in dogs with superficial pyoderma and to compare them with those of oral cephalexin given at 15 mg/kg twice daily.

Methods: Twenty dogs with superficial pyoderma were treated with cephalexin at 30 to 60 mg/kg orally once daily (group A) and compared with 20 dogs treated at a dose of 15 to 30 mg/kg orally twice daily (group B). Dogs were treated until 14 days after clinical remission. Type and distribution of lesions, pruritus and general health status were assessed every 14 days using a numerical scale until 14 days after treatment discontinuation. Total scores for each evaluation day were compared between the two groups as well as time to obtain resolution and percentage of relapses.

Results: Resolution of superficial pyoderma was obtained in all dogs in 14 to 42 days (median 28 days for both groups), with no difference between groups. Six dogs experienced vomiting or diarrhoea but did not require discontinuation of the treatment. Only one dog (in group A) relapsed nine days after treatment discontinuation.
Clinical Significance: Once-daily cephalexin is as effective as twice-daily cephalexin in the treatment of canine superficial pyoderma.

****
Evaluation of antibodies against feline coronavirus 7b protein for diagnosis of feline infectious peritonitis in cats

Kennedy MA, Abd-Eldaim M, Zika SE, Mankin JM, Kania SA. AJVR 2008; 69: 1179-1182.

Objective—To determine whether expression of feline coronavirus (FCoV) 7b protein, as indicated by the presence of specific serum antibodies, consistently correlated with occurrence of feline infectious peritonitis (FIP) in cats.

Sample Population—95 serum samples submitted for various diagnostic assays and 20 samples from specific-pathogen–free cats tested as negative control samples.

Procedures—The 7b gene from a virulent strain of FCoV was cloned into a protein expression vector. The resultant recombinant protein was produced and used in antibody detection assays via western blot analysis of serum samples. Results were compared with those of an immunofluorescence assay (IFA) for FCoV-specific antibody and correlated with health status.

Results—Healthy IFA-seronegative cats were seronegative for antibodies against the 7b protein. Some healthy cats with detectable FCoV-specific antibodies as determined via IFA were seronegative for antibodies against the 7b protein. Serum from cats with FIP had antibodies against the 7b protein, including cats with negative results via conventional IFA. However, some healthy cats, as well as cats with conditions other than FIP that were seropositive to FCoV via IFA, were also seropositive for the 7b protein.

Conclusions and Clinical Relevance—Expression of the 7b protein, as indicated by detection of antibodies against the protein, was found in most FCoV-infected cats. Seropositivity for this protein was not specific for the FCoV virulent biotype or a diagnosis of FIP.